<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="Objectives: Here, we evaluate the ability of CPC to disrupt" exact="influenza" post="viruses in vitro and in vivo. Methods: The virucidal"/>
 <result pre="CPC was evaluated against susceptible and oseltamivir- resistant strains of" exact="influenza" post="viruses. The effective virucidal concentration (EC) of CPC was"/>
 <result pre="was evaluated using transmission electron microscopy (TEM). The ability of" exact="influenza" post="virus to develop resistance was evaluated after multiple passaging"/>
 <result pre="the efficacy of CPC in formulation to prevent and treat" exact="influenza" post="infection was evaluated using the PR8 murine influenza model."/>
 <result pre="and treat influenza infection was evaluated using the PR8 murine" exact="influenza" post="model. Results: The virucidal effect of CPC occurred within"/>
 <result pre="ranging between 5 to 20 μg/mL, for most strains of" exact="influenza" post="tested regardless of type and resistance to oseltamivir. Examinations"/>
 <result pre="CPC possesses virucidal activity against susceptible and resistant strains of" exact="influenza" post="virus by targeting and disrupting the viral envelope. Substantial"/>
 <result pre="substantial morbidity and mortality worldwide [ 1 – 5]. Globally," exact="influenza" post="is estimated to adversely affect up to 5% to"/>
 <result pre="20% to 30% of children each year [ 6]. Annual" exact="influenza" post="epidemics in the United States result in nearly 600,000"/>
 <result pre="visits [ 7]; in addition, the total economic burden of" exact="influenza" post="exceeds $80 billion. Current prevention strategies for influenza are"/>
 <result pre="burden of influenza exceeds $80 billion. Current prevention strategies for" exact="influenza" post="are dependent on the use of anti-influenza medications and"/>
 <result pre="are approved in the United States to prevent and treat" exact="influenza" post="[ 8, 9]. However, the use of antiviral medications"/>
 <result pre="14 – 16]. While the most effective way to prevent" exact="influenza" post="disease and its severe outcomes is by vaccination, current"/>
 <result pre="the development of effective novel strategies to prevent and treat" exact="influenza" post="disease is a significant unmet need. Cetylpyridinium chloride (CPC)"/>
 <result pre="viruses. Here, we evaluated CPC efficacy against the prototypical respiratory" exact="influenza" post="virus demonstrating: (1) direct virucidal activity against influenza, (2)"/>
 <result pre="activity following exposure, (3) viral ultrastructure disruption, (4) absence of" exact="influenza" post="resistance following prolonged exposure, and (5) prevention and treatment"/>
 <result pre="resistance following prolonged exposure, and (5) prevention and treatment of" exact="influenza" post="infection in a murine model. MATERIALS AND METHODS Viral"/>
 <result pre="AND METHODS Viral Strains: Influenza strains were obtained from national" exact="influenza" post="repositories: influenza A/Victoria/3/1975 (H3N2), A/Virginia/1/2009 (H1N1), B/Lee/40, oseltamivir-resistant A/"/>
 <result pre="Viral Strains: Influenza strains were obtained from national influenza repositories:" exact="influenza" post="A/Victoria/3/1975 (H3N2), A/Virginia/1/2009 (H1N1), B/Lee/40, oseltamivir-resistant A/ California/08/2009 (H1N1)pdm09"/>
 <result pre="VR-1535, IRR# FR-202, IRR# FR-486), and a clinical strain of" exact="influenza" post="A (H1N1pdm09) virus which was propagated from a patient"/>
 <result pre="50, Prism; v6.0 software). Influenza Cell Culture: Growth of the" exact="influenza" post="virus was performed as previously described [ 31]. Briefly,"/>
 <result pre="MDCK were grown to 90% confluence followed by inoculation with" exact="influenza" post="virus at a multiplicity of infection (MOI) of 0.1"/>
 <result pre="microscopy (TEM): Influenza virus (B/Lee/40) was chosen as a prototypical" exact="influenza" post="virus and was treated with 50 μg/mL CPC for"/>
 <result pre="(LD 50, 8.0 x 10 3 pfu/mouse) with the mouse-adapted" exact="influenza" post="strain A/Puerto Rico/8/1934 H1N1 (PR8, ATCC). Viral stocks were"/>
 <result pre="assessment of therapeutic efficacy of ARMS-I, mice were challenged with" exact="influenza" post="virus as above, and then treated with ARMS-I (10"/>
 <result pre="the percentage effective concentration of CPC (EC 50) against all" exact="influenza" post="viruses ranged between 5 μg/mL and 12.5 μg/mL ("/>
 <result pre="(H1N1:12.5 ± 5.6 μg/mL, H3N2: 10 ± 5.0 μg/mL), whereas" exact="influenza" post="B was significantly more susceptible to the disrupting effects"/>
 <result pre="virucidal concentration (EC 50) and therapeutic index of CPC against" exact="influenza" post="viruses. Virus (ATCC Strain Number) EC 50 (Range) Therapeutic"/>
 <result pre="we observed that CPC conferred a 2 log reduction in" exact="influenza" post="virus by TCID 50 (EC 2log) at ≤20 μg/mL"/>
 <result pre="50 (EC 2log) at ≤20 μg/mL (EC 2log) for all" exact="influenza" post="strains tested. Again, influenza B appeared more susceptible to"/>
 <result pre="≤20 μg/mL (EC 2log) for all influenza strains tested. Again," exact="influenza" post="B appeared more susceptible to CPC than influenza A"/>
 <result pre="tested. Again, influenza B appeared more susceptible to CPC than" exact="influenza" post="A (4 μg/mL vs 20 μg/mL respectively). To assess"/>
 <result pre="assess if the susceptibility to CPC is different in oseltamivir-resistant" exact="influenza" post="strains, we compared the virucidal activity of CPC against"/>
 <result pre="showed that CPC was effective against both susceptible and resistant" exact="influenza" post="strains. Table 1 shows the EC 50 for resistant"/>
 <result pre="influenza strains. Table 1 shows the EC 50 for resistant" exact="influenza" post="A and B viruses were both 8 μg/mL, while"/>
 <result pre="(within minutes of exposure) antiviral activity against susceptible and resistant" exact="influenza" post="virus. Figure 2. Semi-logarithmic time-kill curves of influenza exposed"/>
 <result pre="and resistant influenza virus. Figure 2. Semi-logarithmic time-kill curves of" exact="influenza" post="exposed to EC50 concentrations of CPC at increasing exposure"/>
 <result pre="except for FluB. Isolate 40 is a clinical strain of" exact="influenza" post="A (H1N1pdm09) virus propagated from a patient sample. B)"/>
 <result pre="= 3 experimental replicates. Mechanism of action of CPC against" exact="influenza" post="virus involves rapid disruption of the viral envelope The"/>
 <result pre="the viral envelope The mechanism of action of CPC against" exact="influenza" post="virus was evaluated using time-course and TEM analyses. First,"/>
 <result pre="influenza virus was evaluated using time-course and TEM analyses. First," exact="influenza" post="virus was exposed to CPC for increasing periods of"/>
 <result pre="the remaining intact virus was titered by HA. Exposure of" exact="influenza" post="virus to CPC for more than 5 minutes caused"/>
 <result pre="CPC for 90 minutes led to a 90% decrease in" exact="influenza" post="titer ( Figure 2A). Second, TEM analyses showed that"/>
 <result pre="TEM analyses showed that while the viral envelope of untreated" exact="influenza" post="viruses was intact, exposure to CPC led to disruption"/>
 <result pre="disrupts the integrity of the viral envelope and morphology of" exact="influenza" post="virus. (A) Untreated influenza virus, (B, C) influenza virus"/>
 <result pre="the viral envelope and morphology of influenza virus. (A) Untreated" exact="influenza" post="virus, (B, C) influenza virus treated with 50 μg/mL"/>
 <result pre="morphology of influenza virus. (A) Untreated influenza virus, (B, C)" exact="influenza" post="virus treated with 50 μg/mL CPC for 5 minutes."/>
 <result pre="(9/200) were disrupted. To further confirm that CPC disrupts the" exact="influenza" post="virus envelope, we used ELISA to monitor the release"/>
 <result pre="μg/mL. Taken together, these results demonstrate that CPC acts against" exact="influenza" post="virus by rapid disruption of the viral envelope. Figure"/>
 <result pre="= 8 experimental replicates, shown as mean ± SD. Mean" exact="influenza" post="nucleoprotein levels in the presence of CPC were compared"/>
 <result pre="to CPC does not induce the development of resistance in" exact="influenza" post="virus To evaluate the potential of CPC to induce"/>
 <result pre="To evaluate the potential of CPC to induce drug resistance," exact="influenza" post="virus was exposed to sub-inhibitory concentrations of CPC, and"/>
 <result pre="exposure was determined ( Figure 5). Figure 5. Exposure of" exact="influenza" post="to 3 sub-inhibitory concentrations of CPC for 10 passages"/>
 <result pre="Ten passages, with 3–4 days exposure per passage, of each" exact="influenza" post="strain were performed for all concentrations of CPC. The"/>
 <result pre="change in EC 50) was seen in any strain of" exact="influenza" post="at any tested concentration of CPC, n = 3"/>
 <result pre="This definition is more stringent than that used for other" exact="influenza" post="medications [ 35]. No increase in EC 50 was"/>
 <result pre="CPC for 10 passages that was not significant. Of note," exact="influenza" post="B susceptibility to CPC continued to be comparable to"/>
 <result pre="susceptibility to CPC continued to be comparable to that of" exact="influenza" post="A. These results suggested that CPC has a low"/>
 <result pre="suggested that CPC has a low potential to select for" exact="influenza" post="virus resistance consistent with its mechanism of action. Orally"/>
 <result pre="Orally applied CPC formulation exhibits prophylactic and therapeutic efficacy against" exact="influenza" post="infection in a murine model The clinical formulation of"/>
 <result pre="tested whether ARMS-1 conferred protection from the widely used mouse-adapted" exact="influenza" post="H1N1 strain PR8 [ 36] in both prophylactic and"/>
 <result pre="PR8 [ 36] in both prophylactic and therapeutic models of" exact="influenza" post="infection. Evaluation of the prophylactic efficacy of ARMS-I showed"/>
 <result pre="We found that CPC is active against susceptible and oseltamivir-resistant" exact="influenza" post="strains. CPC disrupted influenza particles rapidly, within minutes of"/>
 <result pre="is active against susceptible and oseltamivir-resistant influenza strains. CPC disrupted" exact="influenza" post="particles rapidly, within minutes of exposure, analogous to CPC's"/>
 <result pre="directly disrupt the membranes and subsequently inhibit infection of pathogenic" exact="influenza" post="viruses. Lastly, we found that the clinical formulation of"/>
 <result pre="Here we demonstrate that the EC 50 of CPC against" exact="influenza" post="viruses is within a clinically meaningful range. All influenza"/>
 <result pre="against influenza viruses is within a clinically meaningful range. All" exact="influenza" post="strains had CPC-associated EC 50 and EC 2log well"/>
 <result pre="MDCK cells consistent with a clinically viable therapeutic index. Interestingly," exact="influenza" post="B had lower EC 50 and EC 2log compared"/>
 <result pre="B had lower EC 50 and EC 2log compared to" exact="influenza" post="A suggesting that this strain is more susceptible to"/>
 <result pre="of CPC. The reasons for this remain unclear as both" exact="influenza" post="A and B derive their envelope from the host"/>
 <result pre="lipid species of the viral envelope revealed subtle differences between" exact="influenza" post="A and B strains [ 39]. As these bilayers"/>
 <result pre="protective signal [ 34]. The virucidal kinetics of CPC against" exact="influenza" post="viruses sensitive or resistant to oseltamivir were similar to"/>
 <result pre="disrupts the viral envelope. Although these experiments were performed using" exact="influenza" post="B as a prototype virus, we expect the results"/>
 <result pre="prototype virus, we expect the results to be similar with" exact="influenza" post="A. This observation is in agreement with the known"/>
 <result pre="common annual epidemic of these viral pathogens in addition to" exact="influenza" post="highlight the unmet need for broad anti-virals. The potential"/>
 <result pre="binding to the microbial lipid bilayer, and CPC acts against" exact="influenza" post="by disrupting the lipid envelope, which is analogous to"/>
 <result pre="unlikely to be influenced by mutation. We have shown that" exact="influenza" post="strains had no significant increase in EC 50 after"/>
 <result pre="in IC 50 [ 43, 44]. However, continued exposure of" exact="influenza" post="to CPC beyond 10 passages should be performed to"/>
 <result pre="in vivo trials in ferrets, another important animal model for" exact="influenza" post="infection, to assess the potential of CPC-based therapies to"/>
 <result pre="to assess the potential of CPC-based therapies to protect against" exact="influenza" post="disease. In conclusion, we demonstrated that CPC shows significant"/>
 <result pre="In conclusion, we demonstrated that CPC shows significant activity against" exact="influenza" post="via direct virucidal activity by disruption of the viral"/>
 <result pre="We submit that CPC has the ability to protect against" exact="influenza" post="respiratory tract infections and should be considered for further"/>
 <result pre="Esper F Cetylpyridinium chloride (CPC) exhibits potent, rapid activity against" exact="influenza" post="viruses in vitro and in vivo . Pathogens and"/>
 <result pre=", Tapper ML , Uyeki TM , Zimmerman RK Seasonal" exact="influenza" post="in adults and children--diagnosis, treatment, chemoprophylaxis, and institutional outbreak"/>
 <result pre="Weintraub E , Bridges CB The annual impact of seasonal" exact="influenza" post="in the US: measuring disease burden and costs. Vaccine."/>
 <result pre="C, Prevention. Antiviral agents for the treatment and chemoprophylaxis of" exact="influenza" post="--- recommendations of the Advisory Committee on Immunization Practices"/>
 <result pre="R , Thompson MJ Neuraminidase inhibitors for preventing and treating" exact="influenza" post="in healthy adults and children . Cochrane Database Syst"/>
 <result pre="between adverse clinical outcome in human disease caused by novel" exact="influenza" post="A H7N9 virus and sustained viral shedding and emergence"/>
 <result pre="JA , collab: Centers for Disease C, Prevention. Surveillance of" exact="influenza" post="vaccination coverage--United States, 2007-08 through 2011-12 influenza seasons ."/>
 <result pre="Prevention. Surveillance of influenza vaccination coverage--United States, 2007-08 through 2011-12" exact="influenza" post="seasons . MMWR Surveill Summ. 2013; 62( 4): 1–"/>
 <result pre=", Rivetti A , Di Pietrantonj C Vaccines for preventing" exact="influenza" post="in healthy adults. Cochrane Database Syst Rev. 2014; 3:"/>
 <result pre="Spencer S , Fry AM Interim estimates of 2013-14 seasonal" exact="influenza" post="vaccine effectiveness - United States, february 2014 . MMWR"/>
 <result pre="Vogt T , Town M , Singleton JA Surveillance of" exact="influenza" post="vaccination coverage--United States, 2007-08 through 2011-12 influenza seasons ."/>
 <result pre="JA Surveillance of influenza vaccination coverage--United States, 2007-08 through 2011-12" exact="influenza" post="seasons . MMWR Surveill Summ. 2013; 62( 4): 1–"/>
 <result pre=", Ludwig S , Schughart K Pathogenicity of different PR8" exact="influenza" post="A virus variants in mice is determined by both"/>
 <result pre="HA Lipid composition of viral envelope of three strains of" exact="influenza" post="virus - not all viruses are created equal ."/>
 <result pre="TF , Finberg RW , Wang JP Evolution of the" exact="influenza" post="A virus genome during development of oseltamivir resistance in"/>
 <result pre="IG In vitro generation of neuraminidase inhibitor resistance in A(H5N1)" exact="influenza" post="viruses. Antimicrob Agents Chemother. 2009; 53( 10): 4433– 40."/>
 <result pre="Y , Boivin G Generation and characterization of recombinant pandemic" exact="influenza" post="A(H1N1) viruses resistant to neuraminidase inhibitors . J Infect"/>
</results>
